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Mini-Abstract:  
In this nationwide Swedish study, later weekday of esophageal cancer surgery entailed 
increased long-term mortality, particularly for earlier tumor stages. The increase in 5-year 
mortality for each later weekday was 7% for all tumor stages, 24% for stages 0-I, 13% for 
stage II, but was not increased for stages III-IV.   
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Abstract  
Objective: To assess whether weekday of surgery influences long-term survival in 
esophageal cancer.  
Summary Background Data: Increased 30-day mortality rates have been reported in patients 
undergoing elective surgery later compared to earlier in the week. 
Methods: This population-based cohort study included 98% of all esophageal cancer patients 
who underwent elective surgery in Sweden in 1987-2010, with follow-up until 2014. The 
association between weekday of surgery and 5-year all-cause and disease-specific mortality 
was analyzed using a multivariable Cox proportional hazards model, providing hazard ratios 
(HRs) with 95% confidence intervals (CIs), adjusted for age, co-morbidity, tumor stage, 
histology, neoadjuvant therapy, and surgeon volume.   
Results: Among 1,748 included patients, surgery conducted Wednesday-Friday entailed 13% 
increased all-cause 5-year mortality compared to surgery Monday-Tuesday (HR=1.13, 95% 
CI 1.01-1.26). The corresponding association was strong for early tumor stages (0-I) 
(HR=1.59, 95% CI 1.17-2.16), moderate for intermediate tumor stage (II) (HR=1.28, 95% CI 
1.07-1.53), and absent in advanced tumor stages (III-IV) (HR=0.93, 95%CI 0.79-1.09). The 
increase in 5-year mortality for each later weekday (discrete variable) was 7% for all tumor 
stages (HR=1.07, 95% CI 1.02-1.12), 24% for early tumor stages (HR=1.24, 95% CI 1.09-
1.41), 13% for intermediate stage (HR=1.13, 95% CI 1.05-1.22), while no increase was found 
for advanced stages (HR=0.98, 95% CI 0.92-1.05). The disease-specific 5-year mortality was 
similar to the all-cause mortality.  
Conclusions: The increased 5-year mortality of potentially curable esophageal cancer 
following surgery later in the week suggests that this surgery is better performed earlier in the 
week.   
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Introduction 
Curatively intended surgery for esophageal cancer (esophagectomy) is one of the most 
extensive standard surgical procedures carried out.1-3 Oncologic therapy is typically used prior 
to esophagectomy.4-6 Both short-term and long-term survival following esophagectomy is 
strongly dependent on the experience of the surgeon.7-11 These findings have prompted 
centralization of esophagectomy to dedicated high-volume centers.6, 12, 13 However, the overall 
5-year postoperative survival is only approximately 30%, and strongly dependent on the 
tumor stage at the time of surgery, with >70% 5-year survival in early stages (0-I), 
approximately 30% in intermediate stage (II), and <10% in advances stages (III-IV).14, 15 
Thus, it is important to identify other modifiable factors that can improve the postoperative 
prognosis. Two large cohort studies found increased 30-day mortality rates in patients who 
underwent elective surgery later compared to earlier in the week.16, 17 These studies included a 
variety of surgical procedures and assessed short-term mortality only, and the suggested 
mechanism was a “weekend effect”, where postoperative complications might be less well 
handled during weekends. We hypothesized that any prognostic effect of the weekday of 
surgery would be stronger for a more extensive surgical procedure such as esophagectomy, 
and that the long-term prognosis would be reduced due to an increased occurrence of tumor 
recurrence. The surgeon and the surgical team might be more focused earlier in the working 
week when completing demanding and time-consuming esophagectomies compared to later in 
the week, which in turn could influence the prognosis. There are, to the best of our 
knowledge, no studies that have addressed the potential influence of weekday of surgery for 
cancer in relation to long-term survival. Therefore, we conducted a study with the aim to test 
whether esophageal cancer surgery conducted during earlier weekdays is followed by a better 
prognosis than surgery conducted later in the week.   
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Methods 
Design 
This nationwide Swedish population-based cohort study tested whether weekday of surgery 
influences the 5-year all-cause or disease-specific mortality following elective esophagectomy 
for esophageal cancer. The included patients represented 98% of all esophageal cancer 
patients in Sweden who underwent surgery during the period January 1, 1987 through 
December 31, 2010, and were followed up until November 13, 2014. Earlier versions of this 
cohort have been described elsewhere.10, 14 All patients in Sweden with a diagnosis of 
esophageal cancer (identified in the Swedish Cancer Registry) who underwent 
esophagectomy (retrieved in the Swedish Patient Registry) were eligible. Detailed clinical 
data were extracted from medical records, retrieved through our Swedish network of 
clinicians established in the mid-1990s as part of another nationwide study.18 The study 
exposure was the day of the week on which elective esophagectomy for esophageal cancer 
was conducted, between Monday and Friday, as retrieved from the Swedish Patient Register. 
The study outcomes, 5-year all-cause mortality and 5-year disease-specific mortality, were 
collected from the Swedish Causes of Death Registry. The 5-year cut-off for mortality 
assessment was used because the vast majority of esophageal cancer patients who die within 5 
years of surgery have tumor recurrence as the cause of death, and deaths occurring later than 5 
years beyond surgery are rarely due to tumor recurrence, as reflected by mortality rates that 
are similar to the corresponding background population.19 The linkages of individuals 
between registers and the identification of their medical records were enabled by the personal 
identity number, an individual 10-digit identifier assigned to each Swedish resident upon birth 
or immigration.20 The study was approved by the Ethical Review Board in Stockholm, 
Sweden.  
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Data from national registers 
The Swedish Cancer Registry records all cancer diagnoses in Sweden since 1958, and was 
used to identify patients (with age and sex) with esophageal cancer, represented by the 
diagnosis codes 150.0, 150.8, or 150.9 according to the 7th version of the International 
Classification of Diseases. This register has 98% nationwide coverage of all esophageal 
cancer cases.21, 22  
The Swedish Patient Registry records all surgical procedures and diagnoses with dates and 
hospitals within in-hospital care in Sweden since 1987.23 Data on esophagectomy, weekday of 
esophagectomy, co-morbidities, and hospital admittances were collected from this register. 
This register has an excellent (99.6%) positive predictive value for the recording of 
esophageal cancer surgery.24  
The Swedish Causes of Death Registry provided dates of death until November 13, 2014, 
which were used to assess all-cause mortality. Information on the causes of death was 
available until December 31, 2013, which was used to assess disease-specific mortality, as 
defined by a recorded esophageal cancer recurrence in the register.  
 
Data from medical records 
A comprehensive data collection of medical records, including surgical charts and 
pathological reviews, was conducted to retrieve all relevant clinical data, including co-
morbidity, tumor stage, tumor location, tumor histology, neoadjuvant therapy, surgery, and 
annual surgeon volume of esophagectomies. The reviewers of the medical records, who were 
kept blinded from the study outcomes, filled in a predefined protocol to include the required 
clinical data in an objective manner. The assessment of the initial reviewer was validated by 
two other reviewers, which showed >90% exact concordance of variables subject to 
interpretation difficulties, e.g. tumor stage.14 Co-morbidity was assessed according to the well 
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validated Charlson co-morbidity index scoring system.25 Tumor stage, location and histology 
were assessed from the pathology reports of the resected tumor specimens. Tumor stage was 
classified according to the TNM classification of the Union Internationale Contre le Cancer 
(UICC).26 Neoadjuvant therapy was infrequently used in Sweden during the study period, 
which was due to the limited support of such treatment until recently.4, 11, 27 When used, the 
neoadjuvant therapy of choice was a combination of chemotherapy and radiotherapy. The 
dominating (95%) surgical procedure throughout the study period was open transthoracic 
esophageal resection with intra-thoracic anastomosis. The preferred esophageal substitute was 
a pulled-up gastric tube, anastomosed to the proximal esophagus in the thorax or neck. The 
surgeon volume variable was created based on a previously described algorithm, where first, 
the primary surgeon’s chronological number of surgeries was calculated for each year over 
the study period. Thereafter, the surgeon with the highest chronological number of surgeries 
at index operation was considered responsible for the surgery. Annual surgeon volume was 
then calculated as the number of times the surgeon had been responsible for a surgery during 
the index year, whereas cumulative surgeon volume was calculated as the chronological 
number of operations the surgeon had been responsible for at the time of the index surgery 
during the inclusion period.10  
 
Statistical analysis 
The weekday variable was analyzed in three ways. First, early weekdays of surgery (Monday-
Tuesday) were compared with late weekdays (Wednesday-Friday). Second, each of the 5 
weekdays was analyzed as separate categories. Third, weekday of surgery was analyzed as a 
discrete variable to evaluate linear trend with the following coding: Monday=1, Tuesday=2, 
Wednesday=3, Thursday=4, and Friday=5. Potential differences in mortality between 
exposure groups were analyzed using a multivariable Cox-proportional hazards model, 
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providing hazard ratios (HRs) with 95% confidence intervals (CIs) adjusted for potential 
confounding factors. Six pre-defined covariates were included in the multivariable model 
because of their known prognostic influence in combination with a possibility that they might 
influence weekday of surgery. These covariates and their categorizations were: 1) age 
(continuous variable), 2) co-morbidity (Charlson index score 0, 1, or ≥2), 3) tumor stage (0-I, 
II, or III-IV), 4) tumor histology (adenocarcinoma or squamous cell carcinoma), 5) 
neoadjuvant treatment (yes or no), and 6) cumulated surgeon volume of esophagectomies (in 
4 equal sized groups; <7, 7-16, 17-46, or >46). We also conducted analyses stratified for the 
six covariates using the same categorization as presented above. To manage missing data, a 
complete case analysis was performed. Since the study period was long, we added an analysis 
restricted to the more recent calendar period (2000-2010). Follow-up ended at date of death or 
end of study period, whichever occurred first. To evaluate the proportional hazards 
assumption, the correlation was calculated between Schoenfeld residuals for the covariates 
and the ranking of individual treatment failure times, and the assumption was met. The 
statistical software SAS 9.4 (SAS Institute, Cary, NC) was used for the data management and 
statistical analysis. 
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Results 
Patients 
Among 1,799 patients who underwent elective surgery for esophageal cancer in 1987-2010, 
representing 98% of all such procedures in Sweden, 51 (2.8%) were excluded due to missing 
data in any of the covariates. Characteristics of the final 1,748 study participants, grouped into 
early (Monday or Tuesday) and later (Wednesday-Friday) weekdays of surgery are presented 
in Table 1. There were no major differences in distribution of age, sex, co-morbidity scores, 
tumor stage, or neoadjuvant therapy between the groups. Adenocarcinoma histology, higher 
surgeon volume, and more recent calendar period were overrepresented in the Monday-
Tuesday group. The 90-day mortality was 10% in the Monday-Tuesday surgery group and 
14% in the Wednesday-Friday group. The absolute 5-year all-cause mortality and the 5-year 
disease-specific mortality were lower when the surgery was conducted on Monday-Tuesday 
compared to Wednesday-Friday (Table 1). 
 
Weekday of surgery and risk of mortality 
The comparison of surgery later in the week (Wednesday-Friday) with earlier in the week 
(Monday-Tuesday) showed an increased all-cause and disease-specific 5-year mortality 
(adjusted HR=1.13, 95% CI 1.01-1.26 and HR=1.15, 95% CI 1.02-1.29, respectively) (Table 
2 and Figure 1). When weekday of surgery was categorized into each of the 5 weekdays, the 
point HRs increased from Wednesday through Thursday to Friday. Compared to surgery on a 
Monday, surgery on a Friday entailed 46% and 44% increased all-cause and disease-specific 
mortality (HR=1.46, 95% CI 1.15-1.85 and HR=1.44, 95% CI 1.13-1.84), respectively. There 
was an average of 7% increased all-cause and disease-specific 5-year mortality for each 
weekday of surgery when weekday was analyzed as a discrete variable (HR=1.07, 95%CI 
1.02-1.12 for both outcomes) (Table 2).  
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In an analysis restricted to surgery conducted during a more recent calendar period (2000-
2010), the risk estimates lost precision, but the point HRs were at least as high as those of the 
total study population (data not shown). When comparing surgery conducted on Fridays with 
Mondays, the HR was 1.90 (95% CI 0.92-3.92) for surgery during the calendar period 2000-
2010.   
   
Weekday of surgery and risk of mortality stratified for six covariates 
Table 3 presents the results comparing the 5-year mortality in relation to early (Monday-
Tuesday) and late (Wednesday-Friday) weekdays stratified for each of the six covariates 
included in the multivariable model. The point HRs of 5-year mortality were higher among 
patients of older age, with a Charlson comorbidity score of 1, with early tumor stages, 
squamous cell carcinoma histology, neoadjuvant therapy, and those who had surgery by 
higher volume surgeons. The clearest finding was the differences between tumor stages. The 
HRs representing all-cause mortality were greatly increased for early tumor stages (0-I) 
(adjusted HR=1.59, 95% CI 1.17-2.16), and moderately increased for intermediate tumor 
stage (II) (HR=1.28, 95% CI 1.07-1.53), while no association remained in advanced tumor 
stages (III-IV) (Table 3). The difference in association between tumor stages was further 
evaluated in an analysis for each weekday of surgery and an analysis using weekday of 
surgery as a discrete variable. These analyses revealed dose-response patterns between later 
weekday of surgery and 5-year mortality in tumor stage 0-I, and to a more moderate level also 
in tumor stage II, while no such pattern was seen for tumor stages III-IV (Table 4). When 
comparing surgery on a Friday with surgery on a Monday, the HR of 5-year all-cause 
mortality was 2.69 (95% CI 1.27-5.71) in tumor stage 0-I, 1.78 (95% CI 1.22-2.59) in stage II, 
and 1.16 (95% CI 0.83-1.60) in stage III-IV. The HRs for weekday of surgery as a discrete 
variable showed an average 24% increase in risk of all-cause mortality for each weekday of 
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surgery for tumor stage 0-I (HR=1.24, 95% CI 1.09-1.41), 13% increase for stage II 
(HR=1.13, 95% CI 1.05-1.22) for, and no increase for tumor stage III-IV (HR=0.98, 95% CI 
0.92-1.05). The HRs assessing all-cause and disease-specific 5-year mortality were similar 
(Tables 2-4). In an analysis excluding the initial 90 days of surgery the associations between 
weekday of surgery and all-cause and disease-specific 5-year mortality remained virtually 
unchanged (data not shown). 
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Discussion 
This study indicates that esophageal cancer surgery performed later in the week is associated 
with increased all-cause and disease-specific 5-year mortality. The risk estimates were evident 
for earlier tumor stages, but not for advanced tumor stages.  
 
It is not feasible to address the relation between the five weekdays of surgery for esophageal 
cancer and risk of mortality with a randomized clinical trial, which left us with an 
observational design. The three main concerns with a cohort design, which was used in the 
present study, are typically selection bias, misclassification, confounding, and loss to follow-
up. However, these concerns were accounted for. First, selection bias was counteracted by the 
population-based design with inclusion of virtually all patients in Sweden who underwent 
surgery for esophageal cancer. Second, the assessment of the study exposure (weekday of 
surgery) and outcome (mortality) was accurate. Third, although residual confounding can 
never be ruled out, potential confounding by all main prognostic factors was carefully 
adjusted for in the analyses. Fourth, there was no loss to follow-up by virtue of the nationwide 
complete population registers available in Sweden in combination with the personal identity 
numbers. Chance is another potential methodological concern, but to enable good precision 
we included all eligible patients in Sweden since 1987 (when the Swedish Patient Registry 
became nationwide) which provided robust risk estimates, for all except for some of the sub-
analyses. This long study period might, on the other hand, introduce confounding by changes 
in the treatment of esophageal cancer over time, particularly introduction of preoperative 
oncologic therapy and centralization of surgery. However, it is unlikely that these changes 
would influence choice of weekday of surgery. Moreover, all risk estimates were adjusted for 
both neoadjuvant therapy and surgeon volume of esophagectomies. Additionally, the analyses 
stratified for calendar periods showed no difference in association between weekday of 
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surgery and mortality. Finally, all esophagectomies done in Sweden are performed in public 
hospitals where the individual surgeon cannot choose the day of scheduled surgery. 
Therefore, factors like the age or experience of the surgeon would not influence the choice of 
operation day in this study. This is in contrast to many other countries where the individual 
surgeon together with his patient can decide what day of the week to operate on.  
 
To the best of our knowledge, this is the first study addressing the role of weekday of cancer 
surgery in relation to long-term survival. Previous research has identified earlier weekday of 
surgery as beneficial in the short term (30 days) following elective surgery for various 
disorders.16, 17 Some research has also revealed that surgical procedures conducted during 
weekends carry higher 30-day mortality compared to surgery performed during weekdays.28 
However, long-term effects were not addressed and the hypothesis of previous studies has 
been that the health care services are of lower quality during weekends. The hypothesis of the 
present study was instead that the surgical precision might to some extent deteriorate later in 
the week due to the workload of the surgeons and the surgical team. The fact that surgery for 
esophageal cancer is among the most challenging surgical procedures carried out could 
contribute to the findings. The results of the present study indicate that the outcomes 
following esophageal cancer surgery might be influenced by the alertness of the surgeon. 
Esophageal cancer surgery typically requires several hours (the average operation duration for 
esophagectomy in Sweden is 6½ hours) of focused work by the surgeon. It might be argued 
that the surgeon is likely to be well-rested earlier in the working week compared to later in the 
week and therefore will find it easier to focus on exhausting and demanding surgery. This in 
turn might result in more precise surgery, followed by a lower risk of later tumor recurrence. 
This hypothesis gains support from the findings of stronger associations in high-volume 
surgeons and in earlier tumor stages. High-volume surgeons might conduct several 
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esophagectomies each week, which is exhaustive. This also indicates that the on-going 
centralization of services might enhance the weekday effects seen in the present study. In 
earlier tumor stages surgery plays a more crucial role for the chance of long-term survival, 
while the lack of association in advanced tumor stages might be due to the low chance of cure 
(<10% 5-year survival).14, 15  
 
The findings of this study need confirmation in other studies. If proven true, these results 
argue in favor of a change of the scheduling of esophageal cancer surgery to the first part of 
the week, while less time-consuming and tiring surgery might be scheduled for later in the 
week. Although this study focused on surgery for esophageal cancer, it is fully possible that 
the results might be generalizable to other challenging surgical cancer procedures, e.g. surgery 
for cancer of pancreas, bile ducts and liver.  
 
In conclusion, this large and population-based cohort study with adjustment for prognostic 
factors and complete follow-up indicates that esophageal cancer surgery for more readily 
surgically curable tumor stages (0-II) is followed by a better all-cause and disease-specific 5-
year survival if conducted earlier during the week compared to later. Thus, changes in the 
scheduling of esophageal cancer surgery might improve the prognosis in patients operated on 
for esophageal cancer.  
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Table	  1.	  Characteristics	  of	  1748	  study	  patients	  who	  underwent	  surgical	  resection	  for	  
esophageal	  cancer	  in	  Sweden	  in	  1987-­‐2010.	  
Characteristic	  
	   Weekday	  of	  surgery	  
	  
Monday-­‐Tuesday	   	   Wednesday-­‐Friday	  
Number	  (%)	   Number	  (%)	  
	  
Total	   	   1083	  (100)	   	   665	  (100)	  
	  
Age	  (in	  years):	  Mean	  (standard	  deviation)	  	   	   65	  (9)	   	   66	  (10)	  
	  Sex	   Men	  	   	   818	  (76)	   	   487	  (73)	  
	  
Women	   	   265	  (24)	   	   178	  (27)	  
	  
Charlson	  co-­‐morbidity	  index	   0	   	   608	  (56)	   	   407	  (61)	  
	  
1	   	   238	  (22)	   	   125	  (19)	  
	  
>1	   	   237	  (22)	   	   133	  (20)	  
	  
Tumor	  stage	   0-­‐I	   	   292	  (27)	   	   119	  (18)	  
	  
II	   	   368	  (34)	   	   271	  (41)	  
	  
III-­‐IV	   	   423	  (39)	   	   275	  (41)	  
	  
Tumor	  histology	   Adenocarcinoma	   	   513	  (47)	   	   255	  (38)	  
	  
Squamous	  cell	  carcinoma	   	   570	  (53)	   	   410	  (62)	  
	  
Neoadjuvant	  therapy	   No	   	   738	  (68)	   	   445	  (67)	  
	  
Yes	   	   345	  (32)	   	   220	  (33)	  
	  
Surgeon	  volume	  	   <7	   	   263	  (24)	   	   219	  (33)	  
	  
7-­‐16	   	   229	  (21)	   	   163	  (25)	  
	  
17-­‐46	   	   289	  (27)	   	   155	  (23)	  
	  
>46	   	   302	  (28)	   	   128	  (19)	  
	  
Calendar	  period	   1987-­‐1999	   	   513	  (47)	   	   420	  (63)	  
	  
2000-­‐2010	   	   570	  (53)	   	   245	  (37)	  
	  
90-­‐day	  all-­‐cause	  mortality	   No	   	   973	  (90)	   	   576	  (87)	  
	  
Yes	   	   110	  (10)	   	   89	  (13)	  
	  
5-­‐year	  all-­‐cause	  mortality	   No	   	   314	  (29)	   	   135	  (20)	  
	  
Yes	   	   769	  (71)	   	   530	  (80)	  
	  
5-­‐year	  disease-­‐specific	  mortality	   No	   	   387	  (36)	   	   169	  (25)	  
	  
Yes	   	   696	  (64)	   	   496	  (75)	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Table	  2.	  Weekday	  of	  surgery	  for	  esophageal	  cancer	  conducted	  in	  1987-­‐2010	  in	  Sweden	  in	  
relation	  to	  5-­‐year	  all-­‐cause	  and	  disease-­‐specific	  mortality,	  presented	  as	  hazard	  ratios	  (HR)	  
with	  95%	  confidence	  intervals	  (CI).	   	   	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
*	  Adjusted	  for	  age,	  comorbidity,	  tumor	  stage,	  tumor	  histology,	  neoadjuvant	  treatment,	  and	  surgeon	  
volume.	  
†	  Discrete	  variable	  to	  evaluate	  linear	  trend.	  
	  
Weekday	  
	  
	  
Number	  
(%)	  
	  
5-­‐year	  all-­‐cause	  
mortality	  	  
HR	  (95%	  CI)*	  
5-­‐year	  disease-­‐
specific	  mortality	  
HR	  (95%	  CI)*	  
	  
Monday-­‐Tuesday	   1083	  (62)	   1	  (reference)	   1	  (reference)	  
Wednesday-­‐Friday	   665	  (38)	   1.13	  (1.01-­‐1.26)	   1.15	  (1.02-­‐1.29)	  
	  
Monday	   498	  (28)	   1	  (reference)	   1	  (reference)	  
Tuesday	   585	  (33)	   1.03	  (0.89-­‐1.18)	   0.99	  (0.85-­‐1.15)	  
Wednesday	   305	  (17)	   1.07	  (0.91-­‐1.27)	   1.07	  (0.90-­‐1.27)	  
Thursday	   261	  (15)	   1.12	  (0.94-­‐1.34)	   1.13	  (0.94-­‐1.35)	  
Friday	   99	  (6)	   1.46	  (1.15-­‐1.85)	   1.44	  (1.13-­‐1.84)	  
	  
Monday-­‐Friday†	   1748	  (100)	   1.07	  (1.02-­‐1.12)	   1.07	  (1.02-­‐1.12)	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Table	  3.	  All-­‐cause	  and	  disease-­‐specific	  5-­‐year	  mortality	  depending	  on	  weekday	  of	  surgery	  for	  
esophageal	  cancer	  conducted	  in	  1987-­‐2010	  in	  Sweden,	  stratified	  by	  six	  covariates,	  presented	  
as	  hazard	  ratios	  (HR)	  with	  95%	  confidence	  intervals	  (CI).	  	  	  	  	  
5-­‐year	  all-­‐cause	  mortality	  
Covariate	   Number	  (%)	   Monday-­‐Tuesday	   Wednesday-­‐Friday	  
	   Reference	   HR	  (95%	  CI)*	  
Age	  (median,	  years)	   <66	  	   892	  (51)	   1	   1.07	  (0.91-­‐1.25)	  
	   ≥66	   856	  (49)	   1	   1.19	  (1.02-­‐1.39)	  
	   	  
Co-­‐morbidity	  score	   0	   1015	  (58)	   1	   1.12	  (0.97-­‐1.30)	  
	   1	   363	  (21)	   1	   1.25	  (0.97-­‐1.60)	  
	   >1	   370	  (21)	   1	   1.04	  (0.82-­‐1.33)	  
	   	  
Tumor	  stage	   0-­‐I	   411	  (24)	   1	   1.59	  (1.17-­‐2.16)	  
	   II	   639	  (37)	   1	   1.28	  (1.07-­‐1.53)	  
	   III+	  IV	   698	  (40)	   1	   0.93	  (0.79-­‐1.09)	  
	   	  
Tumor	  histology	   Adenocarcinoma	   768	  (44)	   1	   1.03	  (0.86-­‐1.23)	  
	   Squamous	  	   980	  (56)	   1	   1.20	  (1.04-­‐1.38)	  
	   	  
Neoadjuvant	  therapy	   No	   1183	  (68)	   1	   1.08	  (0.94-­‐1.24)	  
	   Yes	   565	  (32)	   1	   1.24	  (1.02-­‐1.52)	  
	   	  
Surgeon	  volume	  	   <7	   482	  (28)	   1	   1.12	  (0.92-­‐1.37)	  
	   7-­‐16	   392	  (22)	   1	   0.99	  (0.78-­‐1.24)	  
	   17-­‐46	   444	  (25)	   1	   1.26	  (1.00-­‐1.57)	  
	   >46	   430	  (25)	   1	   1.16	  (0.91-­‐1.49)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5-­‐year	  disease-­‐specific	  mortality	  
Age	  (median,	  years)	   <66	  	   892	  (51)	   1	   1.06	  (0.89-­‐1.25)	  
	   ≥66	  	   856	  (49)	   1	   1.24	  (1.05-­‐1.46)	  
	   	  
Co-­‐morbidity	  score	   0	   1015	  (58)	   1	   1.14	  (0.98-­‐1.32)	  
	   1	   363	  (21)	   1	   1.30	  (1.00-­‐1.69)	  
	   ≥2	   370	  (21)	   1	   1.04	  (0.80-­‐1.35)	  
	   	  
Tumor	  stage	   0-­‐I	   411	  (24)	   1	   1.58	  (1.12-­‐2.22)	  
	   II	   639	  (37)	   1	   1.37	  (1.14-­‐1.66)	  
	   III-­‐IV	   698	  (40)	   1	   0.93	  (0.79-­‐1.09)	  
	   	  
Tumor	  histology	   Adenocarcinoma	   768	  (44)	   1	   1.04	  (0.86-­‐1.25)	  
	   Squamous	  	   980	  (56)	   1	   1.22	  (1.05-­‐1.42)	  
	   	  
Neoadjuvant	  therapy	   No	   1183	  (68)	   1	   1.11	  (0.97-­‐1.28)	  
	   Yes	   565	  (32)	   1	   1.23	  (1.00-­‐1.51)	  
	   	  
Surgeon	  volume	   <7	   482	  (28)	   1	   1.14	  (0.93-­‐1.40)	  
	   7-­‐16	   392	  (22)	   1	   0.99	  (0.78-­‐1.27)	  
	   17-­‐46	   444	  (25)	   1	   1.28	  (1.01-­‐1.62)	  
	   >46	   430	  (25)	   1	   1.19	  (0.92-­‐1.54)	  
	  
*	  Adjusted	  for	  age,	  comorbidity,	  tumor	  stage,	  tumor	  histology,	  neoadjuvant	  treatment,	  and	  surgeon	  
volume.	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Table	  4.	  All-­‐cause	  and	  disease-­‐specific	  5-­‐year	  mortality	  depending	  on	  weekday	  of	  surgery	  for	  
esophageal	  cancer	  conducted	  in	  1987-­‐2010	  in	  Sweden,	  stratified	  by	  tumor	  stage,	  presented	  
as	  hazard	  ratios	  (HR)	  with	  95%	  confidence	  intervals	  (CI).	  
5-­‐year	  all-­‐cause	  mortality	  	  
Tumor	  stage	   Number	  (%)	   Weekday	   HR	  (95%	  CI)*	  
0-­‐I	   130	  (32)	   Monday	   1	  (reference)	  
	   162	  (39)	   Tuesday	   1.07	  (0.74-­‐1.54)	  
	   60	  (15)	   Wednesday	   1.47	  (0.93-­‐2.31)	  
	   49	  (12)	   Thursday	   1.70	  (1.05-­‐2.74)	  
	   10	  (2)	   Friday	   2.69	  (1.27-­‐5.71)	  
II	   157	  (25)	   Monday	   1	  (reference)	  
	   211	  (33)	   Tuesday	   1.24	  (0.97-­‐1.59)	  
	   115	  (18)	   Wednesday	   1.35	  (1.02-­‐1.79)	  
	   114	  (18)	   Thursday	   1.46	  (1.10-­‐1.92)	  
	   42	  (7)	   Friday	   1.78	  (1.22-­‐2.59)	  
III-­‐IV	   211	  (30)	   Monday	   1	  (reference)	  
	   212	  (30)	   Tuesday	   0.90	  (0.74-­‐1.10)	  
	   130	  (19)	   Wednesday	   0.84	  (0.67-­‐1.06)	  
	   98	  (14)	   Thursday	   0.83	  (0.64-­‐1.07)	  
	   47	  (7)	   Friday	   1.16	  (0.83-­‐1.60)	  
	  
0-­‐I	   411	  (24)	   Monday	  to	  
Friday,	  discrete	  
variable	  
1.24	  (1.09-­‐1.41)	  
II	   639	  (37)	   1.13	  (1.05-­‐1.22)	  
III-­‐IV	   698	  (40)	   0.98	  (0.92-­‐1.05)	  
	  
5-­‐year	  disease-­‐specific	  mortality	  
	   HR	  (95%	  CI)*	  
0-­‐I	   130	  (32)	   Monday	   1	  (reference)	  
	   162	  (39)	   Tuesday	   1.11	  (0.73-­‐1.67)	  
	   60	  (15)	   Wednesday	   1.43	  (0.85-­‐2.41)	  
	   49	  (12)	   Thursday	   1.82	  (1.07-­‐3.08)	  
	   10	  (2)	   Friday	   2.57	  (1.08-­‐6.11)	  
II	   157	  (25)	   Monday	   1	  (reference)	  
	   211	  (33)	   Tuesday	   1.18	  (0.91-­‐1.53)	  
	   115	  (18)	   Wednesday	   1.41	  (1.05-­‐1.88)	  
	   114	  (18)	   Thursday	   1.51	  (1.13-­‐2.02)	  
	   42	  (7)	   Friday	   1.86	  (1.26-­‐2.73)	  
III-­‐IV	   211	  (30)	   Monday	   1	  (reference)	  
	   212	  (30)	   Tuesday	   0.87	  (0.71-­‐1.08)	  
	   130	  (19)	   Wednesday	   0.83	  (0.65-­‐1.06)	  
	   98	  (14)	   Thursday	   0.82	  (0.63-­‐1.06)	  
	   47	  (7)	   Friday	   1.11	  (0.80-­‐1.56)	  
	  
0-­‐I	   411	  (24)	   Monday	  to	  
Friday,	  discrete	  
variable	  
1.25	  (1.07-­‐1.44)	  
II	   639	  (37)	   1.16	  (1.07-­‐1.25)	  
III-­‐IV	   698	  (40)	   0.98	  (0.91-­‐1.04)	  
	  
*	  Adjusted	  for	  age,	  comorbidity,	  tumor	  stage,	  tumor	  histology,	  neoadjuvant	  treatment,	  and	  surgeon	  
volume.	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Figure	  1.	  Kaplan-­‐Meier	  survival	  curves	  following	  surgery	  for	  esophageal	  cancer	  conducted	  on	  
Monday-­‐Tuesday	  compared	  to	  Wednesday-­‐Friday.	  The	  surgery	  was	  performed	  in	  1748	  
patients	  in	  Sweden	  during	  1987	  and	  2010.	  	  
	  	  
